ABSTRACT
The detection of antinuclear antibodies is central to the diagnosis and prognosis of systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS) and mixed connective tissue disease (MCTD). Anti-U1-RNP and anti-RNP70 antibodies were assayed in the sera of patients with SLE (n = 114), pSS (n = 54) and MCTD (n = 12). In the SLE group, 34/114 (30%) were anti-U1-RNP positive, and 21/114 (18%) were both anti-RNP70 positive and anti-U1-RNP positive. In the MCTD group, 10/12 (83%) were anti-U1-RNP positive, and 9/12 (75%) were anti-RNP70 positive. Only one individual with pSS was antibody positive (for both anti-U1-RNP and anti-RNP70). All anti-RNP70-positive samples were also anti-U1-RNP positive. Anti-U1-RNP-positive subjects with SLE were younger (p < 0.0001); showed lower concentrations of complement protein 3 (p = 0.03); had lower eosinophil (p = 0.0005), lymphocyte (p = 0.006) and monocyte (p = 0.03) counts; and had accrued less organ damage (p = 0.006) than the anti-U1-RNP-negative SLE patients. However, we observed no significant clinical or laboratory parameter differences between the anti-U1-RNP-positive individuals with/without anti-RNP70 in the SLE group. In conclusion, anti-RNP70 antibodies are not exclusive to MCTD but are rarely detected in pSS and healthy individuals. In SLE, anti-U1-RNP antibodies are associated with a clinical phenotype that resembles MCTD, with hematologic involvement and less damage accrual. Based on our results, the clinical value of subtyping anti-RNP70 in anti-U1-RNP-positive sera appears to be of limited value.
Subject(s)
Antibodies, Antinuclear , Lupus Erythematosus, Systemic , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Humans , Antibodies, Antinuclear/blood , Ribonucleoprotein, U1 Small Nuclear , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/diagnosis , Immunoenzyme Techniques , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Cross-Sectional StudiesABSTRACT
Interstitial lung disease (ILD) sometimes becomes a life-threatening complication of systemic autoimmune diseases; however, little is known about the immune response in lung lesions. We aimed to investigate humoural immunity in ILD associated with rheumatoid arthritis (RA), sjögren's syndrome (SjS), and mixed connective tissue disease (MCTD), using bronchoalveolar fluid (BALF) and serum samples from 15 patients with autoimmune disease associated-ILD. We first showed that BALF contained higher titers of disease-related autoantibodies than serum, suggesting the possibility of autoantibody production in lungs. Next, we produced 326 monoclonal antibodies from antibody-secreting cells in BALF, and the reactivity and their revertants, in which somatic hypermutations were reverted to germline, were analyzed. Among 123 antibodies from RA-ILD, 16 disease-related antibodies (anti-modified protein antibodies and rheumatoid factors) were identified, of which one antibody had both properties. The revertant antibodies changed their target modification in a complicated manner, suggesting that the antibodies were selected against various modifications in lungs. Among 146 antibodies from SjS-ILD and/or MCTD-ILD, seven anti-SSA/Ro60 antibodies and 15 anti-RNP antibodies were identified. Some of the anti-RNP antibodies recognized multiple RNP constituent proteins simultaneously, indicating that epitope spreading may progress in lungs. Our results revealed the existence of an active autoimmunity in the lungs of autoimmune disease associated-ILD.
Subject(s)
Arthritis, Rheumatoid/complications , Autoantibodies/metabolism , Lung Diseases, Interstitial/immunology , Mixed Connective Tissue Disease/complications , Sjogren's Syndrome/complications , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/immunology , Autoantibodies/blood , Autoantibodies/immunology , Bronchoalveolar Lavage Fluid/immunology , Female , Humans , Lung/immunology , Lung/metabolism , Lung/pathology , Lung Diseases, Interstitial/blood , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/pathology , Male , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/immunology , Ribonucleoproteins/immunology , Sjogren's Syndrome/blood , Sjogren's Syndrome/immunologyABSTRACT
OBJECTIVE: To describe the clinical characteristics and outcomes of systemic sclerosis-mixed connective tissue disease (SSc-MCTD) and SSc overlap syndrome. METHODS: We included patients from the Australian Scleroderma Cohort Study who met American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for SSc. Three mutually exclusive groups were created: SSc-MCTD, SSc overlap, and SSc only. Univariate comparison of clinical features was performed by analysis of variance or chi-square test. Survival analysis was performed using Kaplan-Meier (KM) curves and Cox proportional hazards regression models. RESULTS: Of 1,728 patients, 97 (5.6%) had SSc-MCTD, and 126 (7.3%) had SSc overlap. Those with MCTD-SSc were more commonly Asian (18.3% versus 10.1% in SSc overlap, and 3.6% in SSc only; P < 0.0001) and younger at disease onset (38.4 years versus 46.5 or 46.8 years, P < 0.0001). Those with SSc-MCTD or SSc overlap were more likely to have limited cutaneous SSc. All 3 groups had similar frequency of interstitial lung disease (ILD), although pulmonary arterial hypertension (PAH) was less common in SSc overlap. Synovitis and myositis were more common in SSc overlap and SSc-MCTD than in SSc only. KM curves showed better survival in SSc-MCTD than SSc overlap or SSc only (P = 0.011), but this was not significant after adjustment for sex and age at disease onset. SSc-specific antibodies were survival prognostic markers, with antinuclear antibody centromere or anti-RNP conferring better survival than anti-Scl-70 or anti-RNA polymerase III (P = 0.005). Patients with SSc-MCTD and SSc overlap had lower mortality following diagnosis of ILD and PAH than patients with SSc only. CONCLUSION: This study provides insights into the clinical characteristics of patients with SSc-MCTD, SSc overlap, and SSc only and shows that anti-RNP antibodies are associated with better survival than anti-Scl-70 and anti-RNA polymerase III antibodies.
Subject(s)
Autoantibodies/blood , Mixed Connective Tissue Disease/diagnosis , Scleroderma, Systemic/diagnosis , Adult , Aged , Australia , Biomarkers/blood , Disease Progression , Female , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/drug therapy , Mixed Connective Tissue Disease/mortality , Phenotype , Retrospective Studies , Risk Assessment , Risk Factors , Scleroderma, Systemic/blood , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/mortality , SyndromeABSTRACT
We investigated Toll-like receptor (TLR)-3/-7/-8/-9 and interferon (IFN)-α/ß/γ mRNA expression in whole blood and serum IFN-α/ß/γ levels in patients with mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) and in healthy subjects to assess the association between the TLR-IFN expression and severity of and susceptibility to diseases, and identify potential biomarkers. Expression of the IFN-γ, TLR-3 and TLR-8 was detected only in SLE patients. TLR-7, IFN-α and IFN-ß expression was highest in SLE, while TLR-9 expression was highest in SSc patients. In SLE and MCTD patients a strong correlation was observed between TLR-7 and IFN-α expression and IFN-ß and IFN-α expression. In MCTD patients, negative correlation between IFN-α and TLR-9 and TLR-7 and TLR-9 was revealed. TLR-9 expression in anti-U1-70k-negative, anti-C negative and anti-SmB-negative MCTD patients was higher than in MCTD-positive patients. We observed negative correlations between serum IFN-α levels and TLR-7 expression and C3 and C4 levels in SLE patients. In SLE patients we observed that with increased IFN-γ, TLR-3 and TLR-8 expression increased the value of C3 and C4. Our results confirmed that the endosomal TLR-IFN pathway seems to be more important in SLE than in MCTD or SSc, and that IFN-α and IFN-ß may be possible biomarkers for SLE.
Subject(s)
Gene Expression Profiling/methods , Interferons/genetics , Lupus Erythematosus, Systemic/genetics , Mixed Connective Tissue Disease/genetics , Scleroderma, Systemic/genetics , Toll-Like Receptors/genetics , Adult , Aged , Aged, 80 and over , Endosomes/genetics , Endosomes/metabolism , Female , Humans , Interferon-alpha/blood , Interferon-alpha/genetics , Interferon-alpha/metabolism , Interferon-beta/blood , Interferon-beta/genetics , Interferon-beta/metabolism , Interferon-gamma/blood , Interferon-gamma/genetics , Interferon-gamma/metabolism , Interferons/blood , Interferons/metabolism , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/metabolism , Male , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/metabolism , Scleroderma, Systemic/blood , Scleroderma, Systemic/metabolism , Toll-Like Receptor 3/blood , Toll-Like Receptor 3/genetics , Toll-Like Receptor 3/metabolism , Toll-Like Receptor 7/blood , Toll-Like Receptor 7/genetics , Toll-Like Receptor 7/metabolism , Toll-Like Receptor 8/blood , Toll-Like Receptor 8/genetics , Toll-Like Receptor 8/metabolism , Toll-Like Receptor 9/blood , Toll-Like Receptor 9/genetics , Toll-Like Receptor 9/metabolism , Toll-Like Receptors/blood , Toll-Like Receptors/metabolism , Young AdultABSTRACT
OBJECTIVE: Juvenile-onset mixed connective tissue disease (JMCTD) is a chronic inflammatory disease. We have previously demonstrated preclinical atherosclerosis in these patients, now exploring this further by assessing markers of endothelial dysfunction. METHODS: Thirty-three patients with JMCTD and 33 age-and sex-matched controls were included. Soluble intercellular adhesion molecule-1 (sICAM-1), Il-6 and, von Willenbrand factor (vWF) were assayed from blood taken at the time of carotid ultrasound. RESULTS: Our major findings were: (1) Levels of sICAM-1 (P < .001), IL-6 (Pâ¯=â¯.004), and vWF (Pâ¯=â¯.001) were higher, whereas (2) high density lipoprotein cholesterol (<.01) and apolipoprotein A1 (P < .01) were lower in the patient group compared to controls. CONCLUSIONS: Patients with JMCTD had significantly increased levels of markers of endothelial dysfunction.
Subject(s)
Biomarkers/blood , Carotid Artery Diseases/blood , Endothelium, Vascular/metabolism , Intercellular Adhesion Molecule-1/blood , Interleukin-6/blood , Mixed Connective Tissue Disease/blood , von Willebrand Factor/analysis , Adult , Age Factors , Apolipoprotein A-I/blood , Carotid Artery Diseases/diagnosis , Carotid Intima-Media Thickness , Case-Control Studies , Cholesterol, HDL/blood , Female , Humans , Male , Mixed Connective Tissue Disease/diagnostic imaging , Mixed Connective Tissue Disease/drug therapy , Ultrasonography, Doppler, Color , Up-Regulation , Young AdultABSTRACT
Selective immunoglobulin M deficiency (sIgMD) is an immunodeficiency with undefined pathogenesis and commonly presenting with recurrent infections. 1 The European Society for Immunodeficiencies Registry defines sIgMD as a serum IgM level repeatedly below 2 SD of normal with normal levels of serum IgA, IgG and IgG subclasses, normal vaccination responses, absence of T-cell defects and absence of causative external factors. Rarely it can also be associated with autoimmune diseases. 2-7 Here we describe a patient with primary sIgMD; who presented with multiple autoimmune diseases without a history of recurrent infections and we provide a short literature review on sIgMD and autoimmune diseases.
Subject(s)
Autoimmune Diseases/diagnosis , Immunoglobulin M/deficiency , Immunologic Deficiency Syndromes/diagnosis , Mixed Connective Tissue Disease/drug therapy , Mixed Connective Tissue Disease/immunology , Adult , Aftercare , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/therapeutic use , Autoimmune Diseases/complications , Autoimmune Diseases/immunology , Humans , Hydroxychloroquine/administration & dosage , Hydroxychloroquine/therapeutic use , Iloprost/administration & dosage , Iloprost/therapeutic use , Immunoglobulin G/blood , Immunoglobulin M/blood , Immunologic Deficiency Syndromes/complications , Immunologic Deficiency Syndromes/immunology , Infusions, Intravenous , Male , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/diagnosis , Myalgia/diagnosis , Myalgia/etiology , Nifedipine/administration & dosage , Nifedipine/therapeutic use , Synovitis/diagnosis , Synovitis/etiology , Treatment Outcome , Vasodilator Agents/administration & dosage , Vasodilator Agents/therapeutic useABSTRACT
INTRODUCTION: Phosphaturic mesenchymal tumor mixed connective tissue type (PMT/MCT) is the most common type (up to 90%) of phosphaturic mesenchymal tumor (PMT), a rare clinicopathologic entity. Besides overproduction of fibroblast growth factor 23 (FGF23), there is a big variation of immunohistochemical characteristic across types of PMT, which makes it difficult to obtain an early diagnosis of PMT/MCT. As a benign tumor, PMT/MCT usually happens in subcutaneous tissues and leads to nonhealing of wound. A complete excision of PMT/MCT facilitates wound healing. CONCLUSIONS: Review of the existing evidence indicates that early diagnosis of PMT/MCT is critically important when treating PMT/MCT wound. Hence standardization of early diagnosis for PMT/MCT is mandated.
Subject(s)
Hypophosphatemia, Familial/diagnosis , Mesenchymoma/diagnosis , Mixed Connective Tissue Disease/diagnosis , Soft Tissue Neoplasms/diagnosis , Wounds and Injuries/complications , Biomarkers, Tumor/blood , Diagnosis, Differential , Early Detection of Cancer , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/biosynthesis , Humans , Hypophosphatemia, Familial/blood , Hypophosphatemia, Familial/etiology , Mesenchymoma/blood , Mesenchymoma/etiology , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/etiology , Soft Tissue Neoplasms/blood , Soft Tissue Neoplasms/etiology , Wounds and Injuries/bloodABSTRACT
Objectives: To assess the prevalence, extent, progression, functional impact and mortality of interstitial lung disease (ILD) in a nationwide unselected MCTD cohort. Methods: The study cohort included patients with high-resolution CT lung scans available at baseline (n = 135) and at follow-up (n = 119). The extent of disease was expressed as percentage of total lung volume (TLV). Results: ILD was present in 41% of MCTD patients at follow-up. Median (interquartile) extent (% of TLV) was 5 (8) at baseline and 7 (17) at follow-up, mean length 6.4 years later. The lung disease progressed in 19% of patients across the observation period. Predictors of ILD progression were elevated anti-RNP titre [hazard ratio (HR) 1.5, 95% CI: 1.1, 2.0; P = 0.008], presence of anti-ro52 antibodies (HR = 3.5, 95% CI: 1.2, 10.2; P = 0.023), absence of arthritis (HR = 0.2, 95% CI: 0.1, 0.6; P = 0.004) and male gender (HR = 4.0, 95% CI: 1.4, 11.5; P = 0.011) after age and baseline disease adjustments. The risk of death increased by 2.9 (95% CI: 1.1, 7.9; P = 0.038) in patients where disease involved ⩾5% of TLV. Conclusion: Lung disease extent and progression in MCTD are modest. Yet, the extension continues several years after MCTD diagnosis causing lung function decline and increasing the risk of mortality. The study identified male gender, elevated anti-RNP titre, presence of anti-ro52 antibodies and absence of arthritis as the strongest predictors of ILD progression.
Subject(s)
Lung Diseases, Interstitial/mortality , Mixed Connective Tissue Disease/complications , Adult , Antibodies, Antinuclear/blood , Autoantibodies/blood , Cohort Studies , Disease Progression , Female , Follow-Up Studies , Humans , Longitudinal Studies , Lung/physiopathology , Lung Diseases, Interstitial/diagnostic imaging , Lung Diseases, Interstitial/etiology , Lung Diseases, Interstitial/immunology , Male , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/immunology , Prevalence , Proportional Hazards Models , Ribonucleoproteins/immunology , Risk Factors , Sex FactorsSubject(s)
Azathioprine/administration & dosage , Choroid Diseases , Cyclophosphamide/administration & dosage , Methylprednisolone/administration & dosage , Mixed Connective Tissue Disease , Retinal Artery/diagnostic imaging , Retinal Vasculitis , Retinal Vein/diagnostic imaging , Adolescent , Antibodies, Antinuclear/blood , Choroid Diseases/diagnosis , Choroid Diseases/etiology , Choroid Diseases/therapy , Diagnostic Techniques, Ophthalmological , Female , Humans , Immunosuppressive Agents/administration & dosage , Magnetic Resonance Angiography/methods , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/diagnosis , Mixed Connective Tissue Disease/drug therapy , Mixed Connective Tissue Disease/physiopathology , Retinal Vasculitis/diagnosis , Retinal Vasculitis/etiology , Retinal Vasculitis/physiopathology , Retinal Vasculitis/therapy , Treatment Outcome , Visual AcuityABSTRACT
While the relationship between maternal connective tissue diseases and neonatal rashes was described in the 1960s and congenital heart block in the 1970s, the "culprit" antibody reactivity to the SSA/Ro-SSB/La ribonucleoprotein complex was not identified until the 1980s. However, studies have shown that approximately 10-15% of cases of congenital heart block are not exposed to anti-SSA/Ro-SSB/La. Whether those cases represent a different disease entity or whether another antibody is associated has yet to be determined. Moreover, the cutaneous manifestations of neonatal lupus have also been identified in infants exposed only to anti-U1RNP antibodies. In this review, we describe what we believe to be the first case of congenital heart block exposed to maternal anti-U1RNP antibodies absent anti-SSA/Ro-SSB/La. The clinical and pathologic characteristics of this fetus are compared to those typically seen associated with SSA/Ro and SSB/La. Current guidelines for fetal surveillance are reviewed and the potential impact conferred by this case is evaluated.
Subject(s)
Lupus Erythematosus, Systemic/congenital , Ribonucleoprotein, U1 Small Nuclear/immunology , Adult , Antibodies, Antinuclear/blood , Autoantibodies/blood , Autoantigens/immunology , Fatal Outcome , Female , Heart Block/congenital , Heart Block/diagnosis , Humans , Infant, Newborn , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/immunologyABSTRACT
Objective The objective of this paper is to develop novel classification criteria to distinguish between unclear systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) cases. Methods A total of 205 variables from 111 SLE and 55 MCTD patients were evaluated to uncover unique molecular and clinical markers for each disease. Binomial logistic regressions (BLRs) were performed on currently used SLE and MCTD classification criteria sets to obtain six reduced models with power to discriminate between unclear SLE and MCTD patients that were confirmed by receiving operating characteristic (ROC) curve. Decision trees were employed to delineate novel classification rules to discriminate between unclear SLE and MCTD patients. Results SLE and MCTD patients exhibited contrasting molecular markers and clinical manifestations. Furthermore, reduced models highlighted SLE patients exhibiting prevalence of skin rashes and renal disease while MCTD cases show dominance of myositis and muscle weakness. Additionally decision tree analyses revealed a novel classification rule tailored to differentiate unclear SLE and MCTD patients (Lu-vs-M) with an overall accuracy of 88%. Conclusions Validation of our novel proposed classification rule (Lu-vs-M) includes novel contrasting characteristics (calcinosis, CPK elevated and anti-IgM reactivity for U1-70K, U1A and U1C) between SLE and MCTD patients and showed a 33% improvement in distinguishing these disorders when compared to currently used classification criteria sets. Pending additional validation, our novel classification rule is a promising method to distinguish between patients with unclear SLE and MCTD diagnosis.
Subject(s)
Decision Support Techniques , Lupus Erythematosus, Systemic/diagnosis , Mixed Connective Tissue Disease/diagnosis , Area Under Curve , Biomarkers/blood , Chi-Square Distribution , Decision Trees , Diagnosis, Differential , Humans , Logistic Models , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/classification , Lupus Erythematosus, Systemic/epidemiology , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/classification , Mixed Connective Tissue Disease/epidemiology , Phenotype , Predictive Value of Tests , Prevalence , ROC Curve , Reproducibility of ResultsABSTRACT
OBJECTIVE: MCTD is a chronic, immune-mediated disorder defined by the combined presence of serum anti-RNP antibodies and distinct clinical features, including progressive lung fibrosis. The aim of the study was to evaluate the potential impact of anti-SSA (i.e. Ro52 and Ro60) and anti-SSB autoantibodies as markers for disease outcomes in MCTD. METHODS: Stored serum samples from 113 patients included in the cross-sectional, nationwide Norwegian MCTD cohort were screened for the presence of anti-Ro52, anti-Ro60 and anti-SSB by a commercial line immunoassay. Correlation analyses were carried out with clinical parameters, including quantitative lung fibrosis scores by high-resolution CT. Lung fibrosis was defined by reticular pattern changes according to the Fleischner Society CT criteria for interstitial lung disease. RESULTS: Anti-Ro52 antibodies were present in 29%, anti-Ro60 in 19% and anti-SSB in 6% of the MCTD sera. High-resolution CT scoring identified lung fibrosis in 38 of 113 (34%) MCTD patients. Anti-Ro52 antibodies were detected in 50% (19 of 38) of the MCTD patients with lung fibrosis and in 19% (14 of 75) without lung fibrosis (P < 0.001). The odds ratio for the presence of anti-Ro52 antibodies in lung fibrosis was 4.4 (95% CI 1.8, 10.3). Anti-Ro52 antibodies were equally frequent in patients with mild to moderate (eight of 17; 44%) and severe fibrosis (11 of 21; 52%). Anti-Ro52 was not associated with any of the other clinical parameters assessed, nor was anti-Ro60 or anti-SSB. CONCLUSION: Our cross-sectional data suggest that anti-Ro52 antibodies may serve as a potential marker for lung fibrosis in MCTD.
Subject(s)
Antibodies, Antinuclear/immunology , Mixed Connective Tissue Disease/immunology , Pulmonary Fibrosis/immunology , Ribonucleoproteins/immunology , Adult , Antibodies, Antinuclear/blood , Chronic Disease , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/complications , Pulmonary Fibrosis/blood , Pulmonary Fibrosis/etiology , Retrospective StudiesABSTRACT
INTRODUCTION: Systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) are chronic immune-mediated disorders complicated by vascular organ damage. The aim of this study was to examine the serum levels of the markers of neoangiogenesis: endostatin and vascular endothelial growth factor (VEGF), in our unselected cohorts of SSc and MCTD. METHODS: Sera of SSc patients (N = 298) and MCTD patients (N = 162) from two longitudinal Norwegian cohorts were included. Blood donors were included as controls (N = 100). Circulating VEGF and endostatin were analyzed by enzyme immunoassay. RESULTS: Mean endostatin levels were increased in SSc patients 93.7 (37) ng/ml (P < .001) and MCTD patients 83.2 (25) ng/ml (P < .001) compared to controls 65.1 (12) ng/ml. Median VEGF levels were elevated in SSc patients 209.0 (202) pg/ml compared to MCTD patients 181.3 (175) pg/ml (P = .017) and controls 150.0 (145) pg/ml (P < .001). Multivariable analysis of SSc subsets showed that pulmonary arterial hypertension (coefficient 15.7, 95 % CI: 2.2-29.2, P = .023) and scleroderma renal crisis (coefficient 77.6, 95 % CI: 59.3-100.0, P < .001) were associated with elevated endostatin levels. Multivariable analyses of MCTD subsets showed that digital ulcers were associated with elevated endostatin levels (coefficient 10.5, 95 % CI: 3.2-17.8, P = .005). The risk of death increased by 1.6 per SD endostatin increase (95 % CI: 1.2-2.1, P = .001) in the SSc cohort and by 1.6 per SD endostatin increase (95 % CI: 1.0-2.4, P = .041) in the MCTD cohort after adjustments to known risk factors. CONCLUSIONS: Endostatin levels were elevated in patients with SSc and MCTD, particularly SSc patients with pulmonary arterial hypertension and scleroderma renal crisis, and MCTD patients with digital ulcers. Elevated endostatin levels were also associated with increased all-cause mortality during follow-up in both groups of patients. We propose that endostatin might indicate the degree of vascular injury in SSc and MCTD patients.
Subject(s)
Endostatins/blood , Mixed Connective Tissue Disease/blood , Scleroderma, Systemic/blood , Vascular Diseases/blood , Adult , Biomarkers/blood , Blood Vessels/pathology , Cause of Death , Cohort Studies , Female , Humans , Hypertension, Pulmonary/blood , Kaplan-Meier Estimate , Linear Models , Male , Middle Aged , Mixed Connective Tissue Disease/mortality , Multivariate Analysis , Survival Rate , Ulcer/blood , Vascular Endothelial Growth Factor A/blood , Young AdultABSTRACT
INTRODUCTION: Anti-RNP autoantibodies occur either in mixed connective tissue disease (MCTD) (with a frequently favorable prognosis), or in systemic lupus erythematosus (SLE) cases with aggressive major organ disease. It is uncertain how to assess for the risk of severe disease in anti-RNP + patients. METHODS: Following institutional review board-approved protocols, clinical data and blood were collected from patients with known or suspected anti-RNP autoimmunity and normal controls in a cohort study. Samples were screened for parameters of immune activation. Groups were compared based on clinical diagnoses, disease classification criteria, disease activity and specific end-organ clinical manifestations. RESULTS: Ninety-seven per cent of patients satisfying Alarcon-Segovia MCTD criteria also met Systemic Lupus International Collaborating Clinic (SLICC) SLE criteria, while 47% of the anti-RNP + SLE patients also met MCTD criteria. Among SLICC SLE patients, MCTD criteria were associated with reduced rates of renal disease (odds ratio (OR) 4.3, 95% confidence interval (CI) 1.3-14.0), increased rates of Raynaud's phenomenon (OR 3.5, 95% CI 1.3-9.5) and increased serum B-cell maturation antigen, transmembrane activator and CAML interactor and TNFα levels. Circulating immune markers and markers of type I interferon activation were not effective at distinguishing clinical subgroups. CONCLUSIONS: Among anti-RNP patients, the question of MCTD versus SLE is not either/or: most MCTD patients also have lupus. MCTD classification criteria (but not a broad set of immune markers) distinguish a subset of SLE patients at reduced risk for renal disease.
Subject(s)
Autoantibodies/blood , Mixed Connective Tissue Disease/diagnosis , Ribonucleoproteins/antagonists & inhibitors , Adult , Antibodies, Antinuclear/immunology , Autoantibodies/metabolism , Biomarkers/blood , Case-Control Studies , Cohort Studies , Female , Gene Expression , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/immunology , RNA/blood , RNA/genetics , Raynaud Disease/immunology , Ribonucleoproteins/immunology , Risk Assessment/methodsABSTRACT
BACKGROUND: A rapid and sensitive time-resolved fluoroimmunoassay (TRFIA) based on the biotin-streptavidin amplification system was developed for the determination of anticyclic citrullinated peptide (anti-CCP). METHODS: Europium-labeled streptavidin derivatives combined with europium and anhydride of diethylene triamine pentaacetic acid were used to label streptavidin, biotin was coupled with rabbit anti-human IgG to form a biotin-anti-human IgG bridge between streptavidin-europium and the anti-CCP antibody in the immunoassay. The anti-CCP assay was carried out by measuring the fluorescence of Eu(3+) -streptavidin at 615 nm. RESULTS: The presented method produced a wide linear range from 0.58 to 9,463 U/ml, while it was only 591.4-18.48 U/ml when using an ELISA kit, and featured a detection limit up to 0.5 U/ml for anti-CCP. The values determined by the biotin-streptavidin-TRFIA and ELISA correlated well (R(2) = 0.8927). The method was applied to determine anti-CCP in serum samples with satisfied recoveries of 96.45-104.63%. CONCLUSION: The assay results obtained by the present method showed that biotin-streptavidin-amplified TRFIA improve the traditional ELISA kit for anti-CCP detection. Therefore, it offers a better alternative immunoassay in rheumatoid arthritis management.
Subject(s)
Antibodies, Anti-Idiotypic/blood , Autoantibodies/blood , Biotin , Peptides, Cyclic/blood , Streptavidin/analysis , Animals , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Fluoroimmunoassay , Humans , Immunoassay , Limit of Detection , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/diagnosis , Multiple Sclerosis/blood , Multiple Sclerosis/diagnosis , Peptides, Cyclic/immunology , Prognosis , Rabbits , Scleroderma, Systemic/blood , Scleroderma, Systemic/diagnosis , Sjogren's Syndrome/blood , Sjogren's Syndrome/diagnosisABSTRACT
OBJECTIVE: Anticyclic citrullinated peptide antibodies (anti-CCP) are considered specific markers of rheumatoid arthritis (RA) and have been included in the revised classification criteria for RA diagnosis. However, these antibodies have also been detected in patients with other types of chronic inflammatory rheumatism. Our objectives were to identify the prevalence of positive anti-CCP patients in non-RA diseases, to determine the diagnostic value of anti-CCP for the diagnosis of RA, to specify the clinical characteristics of non-RA patients positive for anti-CCP, and to determine the discriminatory value of the levels of anti-CCP in patients among the various diseases. METHODS: We carried out an observational and descriptive study. All the determinations of anti-CCP requested by the 2 rheumatology departments at Cochin Hospital over a period of 18 months were analyzed. Such determinations were requested for 1162 patients in total. Anti-CCP levels were determined with the Euro Diagnostica ELISA kit, with values ≥ 25 U for this test being considered positive. The diagnosis of rheumatic conditions was the responsibility of the treating physician. RESULTS: Anti-CCP antibodies were detected in 357 (30.7%) of the 1162 patients. The prevalence of anti-CCP was 292/417 (70.0%) in RA, 13/122 (10.6%) in patients with psoriatic arthritis, 13/62 (20.9%) in patients with unclassified rheumatism, 11/33 (33.3%) in patients with primary Sjögren syndrome, 5/30 (16.6%) in patients with systemic lupus erythematosus, 3/28 (10.7%) in patients with mixed connective tissue disorder, 3/36 (8.3%) in patients with systemic sclerosis, 7/44 (15.9%) in patients with juvenile arthritis, and 6/220 (2.7%) in patients with noninflammatory diseases. In the population of patients positive for anti-CCP, mean anti-CCP levels were 869.4 (± 978.4) U/ml, with no significant difference between RA [854.8 (± 959.8) U/ml] and any of the non-RA conditions [922.7 (± 1070.0) U/ml]. CONCLUSION: Anti-CCP are a hallmark of RA, but may be observed in other inflammatory, systemic, or mechanical diseases. In this large cohort of patients, the presence of second-generation anti-CCP (anti-CCP2) antibodies is useful in diagnosing RA (70% sensitivity, 91.3% specificity), but examining the levels of these antibodies does not appear to offer further discriminatory power among patients who are anti-CCP2-positive.
Subject(s)
Antibodies, Anti-Idiotypic/blood , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/immunology , Peptides, Cyclic/immunology , Rheumatic Diseases/diagnosis , Rheumatic Diseases/immunology , Adult , Aged , Arthritis, Juvenile/blood , Arthritis, Juvenile/diagnosis , Arthritis, Juvenile/immunology , Arthritis, Psoriatic/blood , Arthritis, Psoriatic/diagnosis , Arthritis, Psoriatic/immunology , Arthritis, Rheumatoid/blood , Biomarkers/blood , Diagnosis, Differential , Female , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/diagnosis , Mixed Connective Tissue Disease/immunology , Retrospective Studies , Rheumatic Diseases/blood , Scleroderma, Systemic/blood , Scleroderma, Systemic/diagnosis , Scleroderma, Systemic/immunology , Sensitivity and Specificity , Sjogren's Syndrome/blood , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/immunologyABSTRACT
The authors report a rare case of a female patient with mixed connective tissue disease (MCTD) with coexisting antiphospholipid syndrome (APS). Five years after the diagnosis of MCTD high concentrations of anticardiolipin (anti-CL) and anti-ß2-glycoprotein (anti-ß2GPI) autoantibodies were present in the patient's serum without thrombotic events. Epstein-Barr virus (EBV) reactivation provoked APS, with the clinical manifestations of livedo reticularis, digital gangrene and leg ulcers. Skin biopsy from the necrotic area showed multiple fibrin microthrombi in the superficial vessels. Corticosteroid pulse therapy, and plasma exchange in combination with synchronized cyclophosphamide was administered, which led to improvement of the digital gangrenes, while no new lesions developed. The number of CD27high plasma cells decreased, and the previous high levels of autoantibodies also normalized in the peripheral blood. In the case of MCTD with coexisting APS combination therapy, including plasmapheresis has beneficial effects.
Subject(s)
Antiphospholipid Syndrome/therapy , Mixed Connective Tissue Disease/complications , Mixed Connective Tissue Disease/therapy , Plasmapheresis , Adrenal Cortex Hormones/administration & dosage , Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/immunology , Biomarkers/blood , Biopsy , Female , Humans , Immunohistochemistry , Immunosuppressive Agents/administration & dosage , Middle Aged , Mixed Connective Tissue Disease/blood , Mixed Connective Tissue Disease/diagnosis , Mixed Connective Tissue Disease/immunology , Pulse Therapy, Drug , Treatment OutcomeABSTRACT
B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are known to be crucial for B cell maturation and survival, and increased expression of these factors in various autoimmune diseases has been reported. Human B cells produce two IgA subclasses: IgA1 and IgA2, the latter being abundant in the distal intestine, saliva, colostrum and bronchial fluid. We investigated these parameters in patients with mixed connective tissue disease (MCTD) complicated by interstitial lung disease (ILD+), and compared them with those in MCTD patients without ILD (ILD-). Sixty-three MCTD patients were divided into two groups: 21 ILD+ patients and 42 ILD- patients. In each patient group we analyzed soluble BAFF/APRIL using ELISA, and IgA1 and IgA2 using double immunodiffusion. Furthermore, we analyzed BAFF-APRIL receptors, BCMA, BAFF-R and TACI, using flow cytometry. The ILD+ patients had significantly higher levels of BAFF/APRIL than the ILD- patients. There were significant correlations between BAFF/APRIL, BAFF/KL-6 and APRIL/KL-6. Although there was no significant inter-group difference in the serum IgA1 level, ILD+ patients had a significantly elevated IgA2 level in comparison with ILD- patients. Moreover, although there were no significant inter-group differences in the expression of BCMA, BAFF-R and TACI on B cells, the expression of BAFF-R was significantly decreased in the ILD+ patients. In recent years, relationships between BAFF/APRIL and IgA subclass have been reported. Our results suggest that an elevated level of BAFF/APRIL drives the maturation of B cells, subsequently leading to IgA2 class switching, and possibly to the development of ILD in patients with MCTD.
Subject(s)
B-Cell Activating Factor/blood , Immunoglobulin A/blood , Lung Diseases, Interstitial/blood , Mixed Connective Tissue Disease/blood , Tumor Necrosis Factor Ligand Superfamily Member 13/blood , Adult , Aged , B-Lymphocytes/immunology , Female , Humans , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/immunology , Male , Middle Aged , Mixed Connective Tissue Disease/complications , Mixed Connective Tissue Disease/immunologyABSTRACT
OBJECTIVE: The objective of this paper is to determine whether patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) possess differential IgM- and IgG-specific reactivity against peptides from the U1 small nuclear ribonucleoprotein particle (U1 snRNP). METHODS: The IgM- and IgG-mediated responses against 15 peptides from subunits of the U1 snRNP were assessed by indirect enzyme linked immunosorbent assays (ELISAs) in sera from patients with SLE and MCTD and healthy individuals (n = 81, 41, and 31, respectively). Additionally, 42 laboratory tests and 40 clinical symptoms were evaluated to uncover potential differences. Binomial logistic regression analyses (BLR) were performed to construct models to support the independent nature of SLE and MCTD. Receiver operating characteristic (ROC) curves corroborated the classification power of the models. RESULTS: We analyzed IgM and IgG anti-U1 snRNP titers to classify SLE and MCTD patients. IgG anti-U1 snRNP reactivity segregates SLE and MCTD from nondisease controls with an accuracy of 94.1% while IgM-specific anti-U1 snRNP responses distinguish SLE from MCTD patients with an accuracy of 71.3%. Comparison of the IgG and IgM anti-U1 snRNP approach with clinical tests used for diagnosing SLE and MCTD revealed that our method is the best classification tool of those analyzed (p ≤ 0.0001). CONCLUSIONS: Our IgM anti-U1 snRNP system along with lab tests and symptoms provide additional molecular and clinical evidence to support the hypothesis that SLE and MCTD may be distinct syndromes.